Medical
AstraZeneca's eVOLVE-Meso Phase 3 Trial: Will Volrustomig Be the Next Mesothelioma Breakthrough?
Paul Danziger
May 28, 2026
AstraZeneca's eVOLVE-Meso Phase 3 tests volrustomig — a bispecific PD-1/CTLA-4 antibody — against standard immunotherapy in 825 pleural mesothelioma patients.
11 min read 7 FAQs
Read